Healthcare provider profile · identity verified

Daniel W Mcgrane, M.D., P.A.

Internal Medicine · ZEPHYRHILLS, FL · NPI 1356358972

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	166	46
Metoprolol Succinate	Metoprolol Succinate	126	36
Potassium Chloride	Potassium Chloride	124	32
Omeprazole	Omeprazole	123	37
Amlodipine Besylate	Amlodipine Besylate	107	33
Bumetanide	Bumetanide	101	27
Losartan Potassium	Losartan Potassium	77	19
Gabapentin	Gabapentin	74	23
Pantoprazole Sodium	Pantoprazole Sodium	74	15
Tamsulosin Hcl	Tamsulosin Hcl	73	26
Atorvastatin Calcium	Atorvastatin Calcium	71	20
Rosuvastatin Calcium	Rosuvastatin Calcium	63	20
Furosemide	Furosemide	61	18
Metformin Hcl	Metformin Hcl	57	14
Simvastatin	Simvastatin	56	17
Trazodone Hcl	Trazodone Hcl	50	14
Dexamethasone	Dexamethasone	49	28
Prednisone	Prednisone	49	21
Zolpidem Tartrate	Zolpidem Tartrate	49	13
Alprazolam	Alprazolam	44	14
Doxycycline Hyclate	Doxycycline Hyclate	44	31
Ropinirole Hcl	Ropinirole Hcl	43	suppressed
Finasteride	Finasteride	42	13
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	42	suppressed
Cephalexin	Cephalexin	39	29
Montelukast Sodium	Montelukast Sodium	39	suppressed
Clopidogrel	Clopidogrel Bisulfate	38	11
Tramadol Hcl	Tramadol Hcl	37	suppressed
Xarelto	Rivaroxaban	37	suppressed
Azithromycin	Azithromycin	36	27
Donepezil Hcl	Donepezil Hcl	35	suppressed
Eliquis	Apixaban	34	suppressed
Clonazepam	Clonazepam	31	suppressed
Carvedilol	Carvedilol	29	suppressed
Lisinopril	Lisinopril	29	suppressed
Sertraline Hcl	Sertraline Hcl	29	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	26	13
Amoxicillin	Amoxicillin	24	17
Glipizide Er	Glipizide	24	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	22	11
Pravastatin Sodium	Pravastatin Sodium	22	suppressed
Citalopram Hbr	Citalopram Hydrobromide	21	suppressed
Clonidine Hcl	Clonidine Hcl	21	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	21	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	20	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	18	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	18	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	18	suppressed
Irbesartan	Irbesartan	18	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	17	suppressed
Hydralazine Hcl	Hydralazine Hcl	17	suppressed
Ibuprofen	Ibuprofen	17	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	17	suppressed
Januvia	Sitagliptin Phosphate	17	suppressed
Propranolol Hcl	Propranolol Hcl	17	suppressed
Sucralfate	Sucralfate	17	suppressed
Atenolol	Atenolol	16	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	16	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	16	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	15	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	14	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	14	suppressed
Lorazepam	Lorazepam	14	suppressed
Lovastatin	Lovastatin	14	suppressed
Spironolactone	Spironolactone	14	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	13	12
Glipizide	Glipizide	13	suppressed
Humulin 70/30 Kwikpen	Insulin Nph Hum/Reg Insulin Hm	13	suppressed
Midodrine Hcl	Midodrine Hcl	13	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	12	suppressed
Amiodarone Hcl	Amiodarone Hcl	12	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	12	suppressed
Cefdinir	Cefdinir	12	suppressed
Lactulose	Lactulose	12	suppressed
Novolin 70-30	Insulin Nph Hum/Reg Insulin Hm	12	suppressed
Entresto	Sacubitril/Valsartan	11	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	11	suppressed
Nystatin	Nystatin	11	suppressed
Paroxetine Hcl	Paroxetine Hcl	11	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error